DIABETIC
EYE DISEASE:

YOU CAN MAKE A DIFFERENCE IN DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA

Through early detection, monitoring, and
timely referral, Doctors of Optometry can play a pivotal role in managing Diabetic Retinopathy
(DR) and Diabetic Macular Edema (DME)1-3

The information provided in this site is intended for U.S. Doctors of Optometry.

LEARN MORE WITH
OUR AVAILABLE
RESOURCES


Diabetic Retinopathy and Diabetic Macular Edema Can Put Your Patients at Risk for Vision Loss.

Learn More

Diabetes Can Put People at Risk of DR and DME

That is why it is critical to act! If you see or suspect DR and/or DME2,3:

Educate patients about living with Diabetic Retinopathy and/or Diabetic Macular Edema and potential treatment options

EDUCATE

your patients about living with DR and/or DME and potential treatment options

Identify and refer appropriate Diabetic Retinopathy and Diabetic Macular Edema patients

REFER

appropriate DR and DME patients for timely intervention

Ensure Diabetic Retinopathy and Diabetic Macular Edema patients visit a retina specialist when appropriate

FOLLOW UP

to ensure patients have visited a retina specialist

Monitor patients with Diabetic Retinopathy and/or Diabetic Macular Edema

MONITOR

your patients with DR and/or DME

Early Action Can be Important to DR and DME Patients.

See Why

The more you know about emerging clinical science and potential therapies for DR and DME, the better you can help inform your patients about how treatment may be able to help.

Learn About a Treatment Option That May Be Able to Help Patients With Diabetic Retinopathy or Diabetic Macular Edema

Find Out More

Our Commitment to You

Regeneron is committed to helping you partner with your patients for comprehensive
care of DR and DME, as well as for care of certain other retinal diseases.

anti-VEGF = anti–vascular endothelial growth factor.

See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information and Indications INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended for U.S. Doctors of Optometry.

References:

  1. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology. 1991;98(5 suppl):823-833.
  2. Care of the Patient With Diabetes Mellitus: Quick Reference Guide. American Optometric Association website. http://bit.ly/2M22OUJ. Accessed January 14, 2020.
  3. Ferrucci S, Yeh B. Diabetic retinopathy by the numbers. Rev Optom. June 15, 2016. http://bit.ly/2KNNJ4E. Accessed January 14, 2020.
  4. Diabetic Retinopathy. Centers for Disease Control and Prevention website. http://bit.ly/2BKTVCTS. Accessed January 14, 2020.
  5. Diabetic Retinopathy. National Eye Institute, National Institutes of Health website. http://bit.ly/2JLRRLW. Accessed January 14, 2020.
  6. Macular Edema. National Eye Institute, National Institutes of Health website. http://bit.ly/2MGKMVG. Accessed January 14, 2020.